www.rattanlifescience.com

The startup develops induced pluripotent stem cell (iPSC)-derived T cells for targeted immunotherapy in cancer and immune disorders. This technology provides a scalable solution for generating personalized T cell therapies, enhancing treatment efficacy and patient outcomes.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

The startup develops induced pluripotent stem cell (iPSC)-derived T cells for targeted immunotherapy in cancer and immune disorders. This technology provides a scalable solution for generating personalized T cell therapies, enhancing treatment efficacy and patient outcomes.